Local view for "http://purl.org/linkedpolitics/eu/plenary/2008-10-22-Speech-3-036"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2008-10-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Variations to the terms of marketing authorisations for medicinal products - Counterfeiting of medicinal products (debate)2
dcterms:Language	"ro"^^xsd:language2
lpv:document identification number	"en.20081022.2.3-036"2
lpv:hasSubsequent	lp_eu:2008-10-22-Speech-3-0372
lpv:speaker	lp:Dumitru Oprea2
lpv:spokenAs	member; EPP-ED (2007-12-18--2008-12-18)3 substitute; CONT (2007-12-17--2008-12-18)3 member; Delegation for relations with South Africa (2008-01-14--2008-12-18)3 member; CULT (2007-12-18--2008-12-18)3 unknown; Partidul Democrat-Liberal (2008-04-08--2008-12-18)3
lpv:translated text	"In many European countries, the procedure for authorising medicines is clear and even well regulated from an official point of view. However, I would like to draw your attention to some authorisation procedures that are too rapid, which then lead to many deaths caused by medicine overdoses, medicines taken on an ad hoc basis, or by medicines which can cause side-effects that have not been investigated sufficiently before. I think that new medicines and improved medicines with miraculous properties are released too easily on the market, but are then withdrawn within a very short time. Who is responsible for their quality and the side-effects they cause? We welcome this initiative for introducing on the market a harmonisation procedure which is unanimously accepted in Europe. However, new medicines should be included as part of an analysis carried out by an international committee of experts."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph